x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0011818
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human, Mouse, Rat |
| Applications | WB |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues surrounding Leu209 of human ATP5A1 protein. Antibodies are purified by protein A and peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | ATP5F1A |
| UniProt No. | P25705 |
| Gene ID | 498 |
| Gene Description | ATP synthase alpha-subunit is a component of the mitochondrial complex V, which functions to generate ATP from ADP. Generation of ATP is catalyzed by ATP synthase. ATP synthase is composed of a soluble catalytic core, F1, and a membrane-spanning proton channel, F0. ATP5A1 is one of five different subunits that comprise the catalytic F1 core. Interestingly, ATP5A1 is genetically linked to neurodevelopmental diseases. Moreover, the genetically linked mutant forms of C9ORF72, the most common genetic causes of amyotrophic lateral sclerosis and frontotemporal dementia, bind to ATP5A1 and alter its protein expression, suggesting that mitochondrial dysfunction may be a major driver of disease in C9ORF72-linked ALS/FTD. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
